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Abstract
Incorporation of locally produced signaling molecules into cell-
derived vesicles may serve as an endogenous mediator delivery
system. We recently reported that levels alpha-2-macroglobulin
(A2MG)-containing microparticles are elevated in plasma from
patients with sepsis. Herein, we investigated the immunomodu-
latory actions of A2MG containing microparticles during sepsis.
Administration of A2MG-enriched (A2MG-E)-microparticles to mice
with microbial sepsis protected against hypothermia, reduced bac-
terial titers, elevated immunoresolvent lipid mediator levels in
inﬂammatory exudates and reduced systemic inﬂammation.
A2MG-E microparticles also enhanced survival in murine sepsis, an
action lost in mice transfected with siRNA for LRP1, a putative
A2MG receptor. In vitro,A 2MG was functionally transferred onto
endothelial cell plasma membranes from microparticles,
augmenting neutrophil–endothelial adhesion. A2MG also modu-
lated human leukocyte responses: enhanced bacterial phagocyto-
sis, reactive oxygen species production, cathelicidin release,
prevented endotoxin induced CXCR2 downregulation and pre-
served neutrophil chemotaxis in the presence of LPS. A signiﬁcant
association was also found between elevated plasma levels of
A2MG-containing microparticles and survival in human sepsis
patients. Taken together, these results identify A2MG enrichment
in microparticles as an important host protective mechanism in
sepsis.
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Introduction
A coordinated host response is a pre-requisite for successful protec-
tion against injury and infection. It is now appreciated that both the
initiation (Gilroy et al, 2004) and resolution (Spite & Serhan, 2010;
Levy et al, 2012; Ortega-Gomez et al, 2013) of inﬂammation are
active processes that under optimal conditions are tightly regulated
to achieve clearance of infection and repair of damaged tissues,
favoring return to homeostasis. Recent work employing quantitative
methods to assess cellular trafﬁcking at the site of injury and/or
infection and the production of mediators during the course of
inﬂammation-resolution has shed light on some of the mechanisms
involved in self-limited versus delayed resolution (Bannenberg et al,
2005; Stables et al, 2011; Chiang et al, 2012). These studies demon-
strate that leukocyte recruitment and trafﬁcking at the site of inﬂam-
mation is regulated via the production of mediators that signal the
onset as well as termination of the inﬂammatory response. Failure
of the host to engage these pathways results in an aberrant response
and persistent inﬂammation (Stables et al, 2011; Chiang et al, 2012;
Barnig et al, 2013).
Inability of the host to contain an invading pathogen is asso-
ciated with a systemic inﬂammatory response (sepsis) that, when
dysregulated, can precipitate impaired tissue perfusion leading to
organ injury (severe sepsis) with or without hypotension (septic
shock). Lack of progress in combating the high mortality and
morbidity associated with severe sepsis, in part reﬂects our
limited understanding of the complex biological pathways that
regulate innate immunity (Riedemann et al, 2003; Goldenberg
et al, 2011).
A novel mode of non-soluble communication between cells has
recently emerged centered around plasma membrane-shed vesicles,
termed microparticles (Distler & Distler, 2010), which complement
intercellular communication driven by soluble mediators (e.g. cyto-
kines and autacoids). The incorporation of mediators, including pro-
teins and lipid mediators, into vesicles is an efﬁcient means of long
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ing of these mediators from the site of origin minimizing dilution
and/or inactivation (Kunder et al, 2009; Norling & Dalli, 2013).
Since alpha-2-macroglobulin (A2MG) levels are elevated in
plasma neutrophil microparticles from a small cohort of septic
patients when compared to plasma microparticles from healthy vol-
unteers (Dalli et al, 2013), we investigated the actions of A2MG con-
taining microparticles in regulating the host responses during
sepsis. Administration of A2MG enriched (A2MG-E) microparticles
following caecal ligation and puncture (CLP) in mice activated the
host endogenous pro-resolving pathways and signiﬁcantly reduced
mortality. A2MG was also found to preserve human leukocyte
responses where it promoted neutrophil chemotaxis and adhesion
in the presence of endotoxin as well as stimulated bacterial phago-
cytosis by leukocytes.
Results
A2MG enriched microparticles are protective in murine sepsis
and increase exudate pro-resolving lipid mediator levels
To determine the role of A2MG containing microparticles in sepsis
we utilized human neutrophil microparticles containing A2MG
(Dalli et al, 2013). We further enriched these microparticles with
A2MG employing an established method that uses energy-induced
conversion (see Materials and Methods for details) and allows for
the incorporation of target products into membrane bound vesicles
(Norling et al, 2011). Using this protocol we obtained microparticles
with ~8 times higher A2MG content (1.3  0.9 versus 10  2.2 ng/
1 9 10
5 microparticles; termed A2MG-E microparticles; Fig 1A and
supplementary Fig S1). We next treated mice with PBS, A2MG-E mi-
croparticles (1 9 10
5/mouse) or the free protein (i.e. not incorpo-
rated into microparticles; sA2MG), 1 h post CLP, a well-established
model of microbial sepsis (Rittirsch et al, 2009). Here we employed
similar amounts of sA2MG to those found in the A2M-E microparti-
cles in order to investigate whether protective actions of A2MG were
dependent on incorporation into microparticles. Administration of
A2M-E microparticles led to a signiﬁcant reduction in 4-day mortal-
ity when compared to mice that were administered PBS or sA2MG
(Fig 1B). sA2MG also afforded a lesser degree of protection from
death when compared to PBS treated mice (Fig 1B).
Having observed that A2M-E microparticles were protective in
murine sepsis we next investigated whether they modulated the
humoral response by analyzing 12 h peritoneal exudates. Using
lipid mediator metabololipidomics we identiﬁed high levels of medi-
ators from both the lipoxygenase and cyclooxygenase pathways
including prostaglandin (PG) D2, leukotriene (LT) B4 and resolvin
(Rv) D2 (Fig 1C). These mediators were identiﬁed in accordance
with published criteria (Yang et al, 2011) that included matching
retention times, fragmentation patterns and at least 6 characteristic
and diagnostic ions for each as illustrated for RvD1 and RvD2
(Fig 1D). Lipid mediator quantiﬁcation was achieved by multiple
reaction monitoring of signature ion pairs for the parent ion (Q1)
and a characteristic daughter ion (Q3; Fig 1C). Administration of
both A2MG-E microparticles and sA2MG signiﬁcantly reduced pro-
inﬂammatory lipid mediator levels including PGD2 (~20–40%,
P < 0.05; Fig 1E) and the potent chemoattractant LTB4 (>50%;
P < 0.05). Of note, administration of A2MG-E microparticles, but
not sA2MG, increased exudate pro-resolving lipid mediator levels
including RvD1, RvD5 and the potent immunoresolvent RvD2
(~100% increase, P < 0.05; Fig 1E). Collectively these ﬁndings dem-
onstrate that A2MG-E microparticles promote a pro-resolving lipid
mediator proﬁle in inﬂammatory exudates from CLP mice (supple-
mentary Fig S2A and B), an action that was not shared with sA2MG.
Microparticles enriched in A2MG enhance bacterial clearance
and reduced inﬂammation in murine sepsis
Since bacterial containment and clearance are critical to controlling
inﬂammatory responses during sepsis we next investigated whether
microparticle incorporated A2MG also regulated these protective
processes. Administration of A2MG-E microparticles 1h post CLP,
markedly reduced local and systemic bacterial loads (Fig 2A) and
protected against hypothermia (Fig 2B). Administration of sA2MG
did not lead to a signiﬁcant reduction in bacterial loads or protection
from hypothermia. Of note, A2MG did not display direct anti-bacte-
rial actions (supplementary Fig S3), thereby suggesting that the
enhanced bacterial containment and clearance found in vivo after
A2MG-E microparticles administration resulted from direct modula-
tion of the host responses.
Assessment of exudate leukocyte counts demonstrated a reduc-
tion in local inﬂammation 12 h post-CLP in mice treated with A2MG-
E microparticles as evidenced by lower exudate leukocyte levels
(~40% reduction in neutrophil counts; P < 0.05; Fig 2C). Of note this
reduction in leukocytes was primarily due to a signiﬁcant reduction
in neutrophils but not monocytes/macrophages (supplementary Fig
S4A) leading to a signiﬁcant increase in the monocyte/macrophage
to neutrophil ratio (supplementary Fig S4B), a hallmark of resolution
(Spite et al, 2009; Chiang et al, 2012). Assessment of exudate cyto-
kine levels demonstrated a signiﬁcant decrease in pro-inﬂammatory
cytokines including IL-1b (~80%, P < 0.05) and TNF-a (~50%,
P < 0.05; supplementary Fig S2C) in A2MG-E microparticles treated
animals. A2MG-E microparticles administration also led to a
decrease in systemic inﬂammation as demonstrated by: (i) a reduc-
tion in neutrophil inﬁltration into the lungs (~65% reduction
P < 0.05; Fig 2D) and (ii) lower plasma pro-inﬂammatory cytokine
levels, including IL-6 (~35%, P < 0.05) and MCP-1 (~70%, P < 0.05;
Fig 2E). Assessment of circulating white blood cell counts demon-
strated an increase in circulating leukocyte levels following A2MG-E
microparticle administration (supplementary Fig S4C). This is in
keeping with a reduction in secondary organ injury and thus a reduc-
tion in neutrophil trafﬁcking to non-infected organs, a hallmark of
sepsis (Qiu et al, 2000). A2MG-E microparticles did not reduce the
soluble response tout-court, since we also found a speciﬁc and signif-
icant elevation in local and circulating levels of IFN-c (~100%
increase; P < 0.05) and IL-5 (Fig 2E and supplementary Fig S2C).
Administration of sA2MG following CLP also led to a reduction in
pro-inﬂammatory cytokine levels in murine exudates and plasma
that included MCP-1 and IL-1b (Fig 2E and supplementary Fig S2C),
yet this treatment did not reduce exudate leukocyte levels (Fig 2C)
nor did it protect against second organ injury (Fig 2B and D). We
also observed a signiﬁcant reduction in monocyte/macrophage lev-
els in the CLP exudates when compared to both PBS and A2MG-E
microparticles treated mice (supplementary Fig S4A). In addition
there were no differences in the number of circulating leukocytes
when compared to PBS treated mice (supplementary Fig S4C). These
ﬁndings suggest that A2MG incorporation into microparticles
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Figure 1.A 2MG-E microparticles enhance survival in murine sepsis and elevate exudate pro-resolving lipid mediator levels.
AA 2MG containing microparticles (A2MG MP) were further enriched with A2MG (A2MG-E MP) and incorporation assessed by ﬂow cytometry and ELISA.
B Kaplan–Meier survival analysis of mice subjected to CLP at time 0 (see Materials and Methods for details) and 1 h later treated with PBS (100 ll i.v.), soluble
A2MG (sA2MG; 0.05 lg/mouse i.v.) or A2MG-E MP (1 × 10
5/mouse i.v.). Results are mean  s.e.m., n = 12 mice per group (
#P < 0.01,
##P < 0.001 versus PBS
treated mice, one tailed log rank test).
C–E CLP mice were treated as in B and sacriﬁced at 12 h. Lipid mediators in peritoneal exudates were assessed using lipid mediator metabololipidomics following
solid phase extraction (see Materials and Methods for details).
C Representative multiple reaction monitoring chromatograms of the identiﬁed lipid mediators in the peritoneal exudates.
D Accompanying MS-MS spectra employed for identiﬁcation.
E Quantiﬁcation of the identiﬁed lipid mediators was achieved by multiple reaction monitoring using parent ion and diagnostic ion in the MS-MS (daughter ion).
Results for E are mean  s.e.m., n = 4–5 mice per group (*P < 0.05 versus PBS treated mice by one way ANOVA).
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29markedly enhances the protective action of this protein in murine
sepsis, resulting in selective modulation of cytokines and immune-
modulatory lipid mediators as well as enhanced bacterial killing that
lead to a reduction in local and systemic inﬂammation.
A2MG microvesicles display protective actions in murine sepsis
Since A2MG microparticles contain a number of proteins
(Dalli et al, 2013) that may also exert protective actions we next
constructed synthetic microvesicles that were selectively loaded
A 
Sepsis A2MG 
-E MP
sA2MG
0
10
20
30
40
50
0
10
20
30
Sepsis A2MG 
-E MP
sA2MG
Exudate neutrophils Exudate leukocytes
C
e
l
l
 
c
o
u
n
t
s
 
 
(
x
1
0
6
/
m
o
u
s
e
)
 
*  * 
N
e
u
t
r
o
p
h
i
l
 
c
o
u
n
t
s
 
 
(
x
1
0
4
 
p
e
r
 
1
0
0
 
m
g
 
t
i
s
s
u
e
)
Lung cell counts
Sepsis A2MG 
-E MP
sA2MG
0
3
6
9
* 
C D 
IL-6
0
10 000
20 000
30 000
40 000
0
IL-10
5000
10 000
15 000 IL-17
0
1000
2000
3000
*
 
*
 
*
 
*
 
IL-1
0
100
200
300
400
*
 
*
 
IFN
0
30
60
90
TNF-
0
1000
2000
3000
0
MCP-1
10 000
20 000
30 000
40 000
IL-23
0
2000
4000
6000
Sepsis
+A2MG-E MP
+sA2MG
*
 
*
*
 
*
 
*
 
*
 
*
 
*
 
(
p
g
/
m
l
)
 
 
(
p
g
/
m
l
)
 
 
E 
B 
B
a
c
t
e
r
i
a
l
 
l
o
a
d
 
(
L
o
g
1
0
 
C
F
U
)
 
sA2MG
2
3
4
5
6
7
8
9
Sepsis A2MG 
-E MP
Blood
** 
sA2MG Sepsis A2MG 
-E MP 
1
5
6
7
8
9
B
a
c
t
e
r
i
a
l
 
l
o
a
d
 
(
L
o
g
1
0
 
C
F
U
)
 
Peritoneal exudates 
** 
20
25
30
35
SepsisA2MG 
-E MP
sA2MG
** 
M
o
u
s
e
 
b
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
o
C
)
 
10
0
30
50
IL-5
*
*
 
Figure 2. Bacterial containment and clearance is enhanced by A2MG-E microparticles reducing local and systemic inﬂammation during microbial sepsis.
Mice were subjected to CLP (see Materials and Methods for details) 1 h later treated with PBS (100 ll i.v.), A2MG-E MP (1 × 10
5 i.v.) or sA2MG (0.05 lg) and sacriﬁced at
12 h. Results A, C–E are mean  s.e.m. A, C–E, n = 6 mice per group; B, n = 12 mice per group (*P < 0.05,* * P < 0.01 versus PBS treated mice by one way ANOVA).
A Aerobic bacterial levels in peritoneal exudates and blood from CLP mice.
B Body temperature at 12 h following CLP.
C Peritoneal exudate leukocyte and neutrophil counts.
D Counts for trapped neutrophils in lungs, as determined by light microscopy, Ly6G staining and ﬂow cytometry.
E Exudate cytokine levels as determined by multiplex array.
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30with a deﬁned amount of A2MG (A2MG-MV; see Materials and
Methods for details) and tested them in murine sepsis. Administra-
tion of A2MG-MV to CLP mice led to a dose dependent reduction in
peritoneal exudate neutrophil counts at 12 h when compared with
mice treated with control microvesicles (cMV; Fig 3A). Treatment of
mice with A2MG-MV also led to a dose-dependent increase in the
number of phagocytosed bacteria in murine peritoneal exudates, as
determined by in situ hybridization and ﬂow cytometry (Fig 3B).
Furthermore, there was a dose dependent reduction in both exudate
(Fig 3C) and plasma (Fig 3D) bacterial loads when compared to
mice treated with cMV. Administration of A2MG-MV also led to a
dose dependent reduction in exudate and plasma levels of pro-
inﬂammatory cytokines, including IL6 and TNF-a (supplementary
Fig S5) as well as second organ injury, as determined by a reduction
in lung MPO levels (Fig 3E). Treatment of mice subjected to CLP
with A2MG-MV signiﬁcantly protected against hypothermia
(Fig 3F). In all cases, doses of 1 9 10
5 and 1 9 10
6 A2MG-MV elic-
ited the most signiﬁcant effects. Administration of A2MG-MV
(1 9 10
6) led to a signiﬁcant reduction in mortality when compared
with mice treated with cMV (Fig 4A). Together these results indicate
that A2MG exerts protective actions in sepsis likely mediating at
least some of the protective actions displayed by A2MG-E MP
(Figs 1 and 2).
To corroborate this further, we next investigated whether the
A2MG receptor, the low-density lipoprotein receptor-related protein
(LRP) 1, mediated these protective actions. Here we employed an
established in vivo transfection system using siRNA to silence LRP1
expression in mice. Mice received either a mock lentiviral vector or
a lentiviral vector containing a siRNA sequence to LRP1. Assess-
ment of peripheral blood LRP1 levels 48 h after transfection demon-
strated a signiﬁcant reduction in peripheral blood LRP1 expression
(~50%; P < 0.05; supplementary Fig S6), conﬁrming the efﬁcacy of
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Figure 3.A 2MG microvesicles dose dependently stimulate bacterial clearance in vivo reducing local and systemic inﬂammation during microbial sepsis.
Microvesicles (cMV; 10
6 capsules per mouse) or microvesicles containing A2MG (A2MG-MV) were administered i.v. at the indicated doses 5 min prior to CLP (see
Materials and Methods for details). Mice were sacriﬁced at 12 h. Results are mean  s.e.m. n = 6 mice per group (*P < 0.05,* * P < 0.01 versus cMV treated mice by one
way ANOVA).
A Peritoneal exudate leukocyte counts.
B Exudate bacterial phagocytosis determined by ﬂow cytometry.
C,D Aerobic bacterial levels in (C) peritoneal exudates and (D) blood from CLP mice.
E Lung MPO levels.
F Body temperature at 12 h following CLP.
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31this approach at reducing LRP1 expression in peripheral blood leu-
kocytes. We next subjected mock transfected or siRNA transfected
mice to CLP, then treated these mice with either PBS or A2M-E MP
and assessed survival over 4 days. There were no signiﬁcant differ-
ences between the two vehicle treated groups with 100% lethality
within 52 h (Fig 4). Administration of A2M-E MP to mice treated
with mock vector signiﬁcantly improved survival, an action that
was lost in mice that were also treated with LRP1 siRNA (Fig 4).
Together these results indicate that in mice LRP1 mediates the pro-
tective actions of A2MG-E MP.
LRP1 mediates the actions of A2MG on human leukocytes
Since A2MG containing microparticles demonstrated protective
actions in murine sepsis we next investigated the cellular and
molecular mechanisms activated by microparticle-A2MG using
isolated human and mouse leukocytes. We used ﬂow cytometry
to assess the relative distribution of LRP1 on human neutrophils.
Here we found that LRP1 immunoreactivity was higher in per-
meabilized cells in comparison to non-permeabilized cells (sup-
plementary Fig S7A) demonstrating that this protein was
expressed both on the plasma membrane and, at higher levels,
in the cytosol. Confocal analysis corroborated LRP1 expression
on the plasma membrane of resting human neutrophils (Fig 5A).
Assessment of LPR1 expression following exposure to LPS dem-
onstrated a signiﬁcant upregulation of LRP1 expression on
human neutrophils plasma membrane (Fig 5A and supplementary
Fig S7B). Incubation of mouse neutrophils with LPS also led to
a signiﬁcant increase in cell membrane LRP1 expression (supple-
mentary Fig S7C). These results suggest that neutrophil activa-
tion leads to LRP1 mobilization from intracellular stores to the
plasma membrane.
Next we investigated the role of LRP1 in mediating the protective
responses of microparticle-A2MG on human primary leukocytes.
Incubation of neutrophils with microparticles containing elevated
A2MG levels, [termed A2MG MP; see Materials and Methods and
Dalli et al (2013) for details] led to a dose dependent increase in
bacterial phagocytosis (Fig 5B), an action that was inhibited when
leukocytes were pre-incubated with an anti-LRP1 antibody. When
human neutrophils were incubated with A2MG MP we found a
signiﬁcant increase in ROS production when the neutrophils were
also incubated with Escherichia coli (Fig 5C), an action inhibited
when cells were pre-incubated with an anti-LRP1 antibody. Similar
results were obtained with macrophages both in terms of bacterial
phagocytosis (Fig 5D) and ROS production (Fig 5E). These results
indicate that leukocyte LRP1 mediates the protective actions of
A2M MP.
In order to assess the role of A2MG in regulating the leukocyte
responses elicited by A2MG MP we next investigated whether
sA2MG regulated macrophage and peripheral blood neutrophil
phagocytosis and ROS production. Incubation of human and
mouse macrophages with sA2MG led to a dose dependent increase
in macrophage phagocytosis (supplementary Figs S8 and S9). Incu-
bation of human macrophages with sA2MG also led to a dose
dependent increase in ROS production when the cells were co-
incubated with E. coli (supplementary Fig S8). These actions of
sA2MG on human macrophages were abrogated when the cells
were pre-incubated with anti-LRP1 antibody (supplementary Fig
S8). sA2MG also elicited an increase in bacterial phagocytosis and
ROS production with human peripheral blood neutrophils, actions
that were sensitive to cell incubation with anti-LRP1 antibody
(supplementary Fig S10).
Another protective response to bacterial invasion is the release of
bactericidal proteins and peptides that aid in the containment and
clearance of the invading pathogen as well as act as signaling mole-
cule guiding the recruitment of leukocytes to the site of inﬂamma-
tion (Wan et al, 2011). Incubation of human peripheral blood
neutrophils in the presence of LPS led to an increase in cathelecidin
levels measured in the cell free supernatants, levels that were fur-
ther enhanced when the neutrophils were also incubated with
sA2MG (supplementary Fig S11). Together these ﬁndings suggest
that A2MG on microparticles engages LRP1 on human leukocytes to
modulate host protective responses.
Microparticle-A2MG promotes neutrophil –
endothelium interactions
Leukocyte ﬁrm adhesion to the vascular endothelium is a key step
in regulating recruitment to the site of inﬂammation (Phillipson &
Kubes, 2011), therefore we next investigated whether microparticle-
A2MG regulated human neutrophil recruitment onto endothelial
cells. Here we incubated (4 h, 37°C) HUVEC with A2MG MP that
led to an increase in neutrophil recruitment (≥25% above TNF-a;
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Figure 4. LRP1 mediates the protective actions of A2MG during
microbial sepsis. Results are mean  s.e.m., n = 10 mice per group
(
§P < 0.05 versus cMV treated mice; *P < 0.05, versus PBS mice;
#P < 0.05,
versus LRP1 KD A2M-E MP mice by one tailed log rank test).
A Microvesicles (cMV; 10
6/mouse) or microvesicles containing A2MG (A2MG-
MV 10
6/mouse) were administered i.v. 5-min prior to CLP (see Materials and
Methods for details) and survival assessed over a 96 h interval.
B Mice were transfected with either mock or LRP1 siRNA (LRP1 KD see
Materials and Methods for details). After 48 h PBS or A2MG-E MP (1 × 10
5
i.v.) were administered i.v. 5 min prior to CLP.
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Figure 5.A 2MG stimulates bacterial phagocytosis by human leukocytes via LRP1. Results are mean  s.e.m. of three individual cell preparations (*P < 0.05,
**P < 0.01 versus PBS incubation;
#P < 0.05 versus A2MG MP incubation by one way ANOVA).
A LRP1 expression was monitored on resting and LPS-stimulated human neutrophils (1 lg/ml, 1 h, 37°C) by confocal microscopy (see Materials and Methods for
details). Results are representative of n = 3 individual cell preparations.
B–E Human neutrophil and macrophage bacterial phagocytosis and ROS production.
B Peripheral blood human neutrophils (1 × 10
5/well).
C Primary human macrophages (1 × 10
4/well) were plated in 96 well plates and incubated with PBS or A2MG MP (10
2–10
5 microparticles per well) 15 min prior
to the addition of BacLight labeled E. coli (1:50 neutrophil/macrophage to bacteria) for 60 min (37°C). In some instances anti-LRP1 (1 lg/ml) antibody was added
30 min prior to the addition of A2MG (right panel).
D Peripheral blood human neutrophils (1 × 10
5/well).
E Primary human macrophages (1 × 10
4/well) were incubated CM-H2DCFDA for 30 min prior to plating in 96 well plates. These were then incubated with PBS or
A2MG MP (10
2–10
5 microparticles per well) 15 min prior to the addition of E. coli (1:50 neutrophil/macrophage to bacteria) for 30 min (37°C) and intracellular
ROS production was determined on a plate reader. In some instances anti-LRP1 (1 lg/ml) antibody was added 30 min prior to the addition of A2MG MP (right panel).
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33Fig 6A) onto the endothelial cell monolayer; whereas neutrophil
adhesion was unchanged when endothelial cells were incubated
with neutrophil microparticles expressing low A2MG levels (n = 3).
We next investigated whether A2MG MP regulated endothelial
adhesion molecule expression. Flow-cytometric analysis did not
reveal any signiﬁcant differences in expression of levels of CD31,
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Figure 6.A 2MG is transferred by microparticles onto endothelial cell plasma membranes and promotes neutrophil adhesion to endothelial cells. Results
are mean  s.e.m. of n = 3–4 distinct microparticle and HUVEC preparations per group (*P < 0.05, versus TNF-a;
#P < 0.05 versus A2MG MP + TNF-a by Student’s t-test
or one way ANOVA).
A HUVEC were incubated with TNF-a (10 ng/ml) in the presence or absence of microparticles expressing elevated A2MG levels (A2MG MP) for 4 ha t37°C. Freshly
prepared neutrophils were then perfused over the monolayer at 1-dyne/cm
2 for 8 min and the number of adherent leukocytes quantiﬁed.
B HUVEC were stimulated with TNF-a (10 ng/ml) with or without A2MG MP (5 × 10
4) for 4 h, these were then ﬁxed, stained using Alexa Fluor
  633-Agglutinin
(Membrane), anti-A2MG antibody (5 lg/ml) and mounted in Probing Antifade medium containing DAPI.
CA 2MG MP were incubated with anti-A2MG antibody (5 lg/ml), or isotype control (Iso; 10 min, RT) prior to incubation with HUVEC monolayer (4 h, 37°C), and
neutrophil perfusion.
D Neutrophils were incubated with anti-LRP1 (5 lg/ml) antibody or isotype control (Iso; 10 min, RT) prior to perfusion over endothelial cells that were incubated with
A2MG MP (4 h, 37°C).
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34CD54, CD62E, CD99 and CD106 on endothelial cell plasma mem-
branes between cells incubated with PBS and cells incubated with
A2MG MP (supplementary Fig S12). Thus, we next investigated
whether microparticle-delivered A2MG directly regulated the neu-
trophil adhesion to endothelial monolayers. Confocal analysis of
endothelial cells incubated with A2MG MP demonstrated a marked
increase in A2MG immunoreactivity on the HUVEC monolayers
(Fig 6B). Therefore we next tested whether this transfer of A2MG by
microparticles was of functional relevance incubating A2MG MP
with anti-A2MG antibody either prior to incubation with HUVEC or
15 min prior to neutrophil perfusion. In both cases incubation of the
microparticles with anti-A2MG antibody abrogated the potentiating
actions of A2MG MP on neutrophil adhesion and returned cell adhe-
sion to the values measured following TNF-a stimulation alone
(Fig 6C and supplementary Fig S13). Collectively, these results sug-
gest that A2MG is delivered onto the endothelial cells plasma mem-
branes by microparticles where it contributes to neutrophil
adhesion to endothelial cells.
We next investigated the role of neutrophil LRP1 in mediating
the pro-adhesive actions of A2MG MP. Here incubation of neutroph-
ils with an anti-LRP1 antibody led to a signiﬁcant reduction in neu-
trophil adhesion when compared with A2MG MP incubated HUVEC,
an effect that was lost when neutrophils were instead incubated
with a relevant isotype control (Fig 6D). Together these results indi-
cate that A2MG is transferred by microparticles on to the endothelial
plasma membrane where it engages LRP1 on the neutrophils pro-
moting ﬁrm leukocyte adhesion.
A2MG modulates neutrophil responses
We further explored the molecular mechanisms by which A2MG
regulated neutrophil recruitment to endothelial cells. For this pur-
pose we incubated human neutrophils with sA2MG, eliminating
the possibility that other microparticle derived proteins could con-
found these analyses, and assessed the expression of the active
conformation of CD11b, the alpha moiety of Mac-1 that is
involved in neutrophil recruitment onto the vascular endothelium
(Edens & Parkos, 2003). Neutrophil incubation with sA2MG
led to a signiﬁcant increase in CD11b neo-epitope exposure
(Fig 7A). The increased CD11b activation was functionally
reﬂected in an enhanced human and mouse neutrophil interaction
with ICAM-1, one of the CD11b ligands (Fig 7B and supplemen-
tary Fig S14).
Chemotactic cues direct leukocytes to the site of injury or infec-
tion. This response is hampered in sepsis where endotoxin upregu-
lates G-protein-coupled receptor kinase 2 (GRK2) reducing cell
surface expression of chemotactic receptors on the neutrophil
plasma membrane (Alves-Filho et al, 2009) resulting in inefﬁcient
neutrophil activation and recruitment (Alves-Filho et al, 2009, 2010;
Liu et al, 2012). Thus, we next investigated whether A2MG can help
rectify aberrant neutrophil responses elicited by endotoxin. Incuba-
tion of neutrophils with sA2MG inhibited LPS-induced GRK2 upreg-
ulation (Fig 7C). This was of functional relevance since sA2M
prevented LPS mediated down regulation of CXCR2 (IL-8 receptor)
on the neutrophil plasma membrane (Fig 7D) and preserved neutro-
phil chemotactic responses (Fig 7E).
In order to investigate whether these ﬁndings held true in vivo
we investigated if A2MG regulated early neutrophil recruitment to
the site of infection during on-going CLP. Administration of
A2MG MV prior to CLP led to a dose-dependent increase in the
number of peritoneal exudate neutrophils collected at 6 h when
compared to mice treated with MV alone (Fig 7F). Collectively,
these results demonstrate the protective actions of A2MG in main-
taining key neutrophil responses that are often compromised in
sepsis.
Elevated plasma levels of A2MG expressing microparticles
correlate with survival in human sepsis
In view of these potentially clinically important properties displayed
by A2MG, especially when incorporated into microparticles, we
measured plasma levels of A2MG containing microparticles in
patients with sepsis caused by community-acquired pneumonia
within 24 h of admission to the intensive care unit (ICU). In order
to better appreciate the impact of these microparticles in sepsis we
compared survivors (i.e. patients that were alive 28 days post
admission to the intensive care unit; n = 25) with non-survivors
(i.e. patients that died within 28 days of admission to the ICU;
n = 25). There were no differences in co-morbidities or adjuvant
treatments (supplementary Tables S2 and S3) between survivors
and non-survivors.
Levels of A2MG containing microparticles were higher in survi-
vors then in both non-survivors and healthy volunteers (HV) as
determined by the number of A2MG and Annexin V positive events
detected using ﬂow cytometry (Fig 7G). In addition the increase in
plasma A2MG containing microparticles was found to be signiﬁ-
cantly correlated with disease outcome (Fig 7G).
Collectively, these results suggest that microparticle enrichment
with A2MG is an endogenous host protective mechanism that pre-
serves key leukocyte responses during sepsis to engage pro-resolv-
ing and life saving pathways.
Discussion
The investigations reported herein demonstrate that A2MG incorpo-
rated into microparticles activated distinct host protective responses
in murine sepsis, when compared to sA2MG, leading to enhanced
bacterial containment and clearance ultimately resulting in
improved survival. Microparticle-A2MG was also found to regulate
human leukocyte responses, where it promoted neutrophil recruit-
ment to endothelial cells. In addition, A2MG preserved neutrophil
chemotactic responses in the presence of endotoxin and stimulated
bacterial phagocytosis and ROS production via its receptor, LRP1.
These ﬁndings support the hypothesis that A2MG incorporation into
microparticles may potentiate the protective actions of A2MG in sep-
sis by activating distinct pro-resolving and tissue protective path-
ways.
A2MG is an evolutionarily conserved tetrameric glycoprotein
(Qin et al, 2010), expressed by a number of cell types in its native
form and is one of the major circulating anti-proteinases in verte-
brates (Rehman et al, 2013). Of note A2MG is the only plasma pro-
teinase able to inhibit a wide range of mammalian proteases in
addition to parasite-derived proteinases, including those from Trich-
ophyton mentagrophytes (causal agent of ringworm) and the neutral
proteinase of Fusiformis nodosus [causal agent of ovine foot-root;
for a detailed review (Rehman et al, 2013)]. In mammals, A2MG is
predominantly found as a heterotetramer of 160–185 kDa subunits.
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35Upon exposure to proteases or reactive amines A2MG changes
conformation, thereby initiating high afﬁnity binding to several
cytokines including TNF-a and IL-6. This conformational change
also exposes a receptor-binding domain on the protein that leads to
its rapid clearance via endocytosis (Imber & Pizzo, 1981). This
mechanism has been proposed to mediate the protective actions of
A2MG in experimental models of sepsis, by quenching circulating
cytokine levels (Webb & Gonias, 1998), in addition to the ability of
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Figure 7.A 2MG preserves neutrophil responses in the presence of endotoxin: correlation of A2MG containing microparticles levels with survival in sepsis.
AC D 11b neo-epitope exposure following LPS treatment (1 lg/ml, 60 min, 37°C) of isolated human neutrophils was determined by ﬂow-cytometry.
B Neutrophil interaction with ICAM-1 coated chambers following incubation with LPS (1 lg/ml, 60 min, 37°C) or A2MG (10 nM, 15 min, 37°C) followed by LPS
(1 lg/ml, 60 min, 37°C) under ﬂow.
C GRK2 expression was assessed by western blotting in human neutrophils incubated with PBS, LPS (1 lg/ml, 60 min, 37°C) or A2MG (10 nM, 5 min, 37°C) followed by
LPS (1 lg/ml, 60 min, 37°C).
D CXCR2 expression on human neutrophils incubated with LPS with or without A2MG (60 min, 37°C) as determined by ﬂow cytometry.
E Neutrophil chemotaxis towards IL8 (100 ng/ml) following cell incubation with LPS (1 lg/ml) and A2MG as indicated. Results are mean  s.e.m. of n = 3–4 distinct
microparticle and neutrophil preparations (*P < 0.05,* * P < 0.001 versus PBS incubations,
#P < 0.05 versus LPS;
§P < 0.05 versus IL8+LPS by one way ANOVA).
F Control MV; (10
6/mouse) or A2MG-MV were administered i.v. at the indicated doses 5 min prior to CLP (see Materials and Methods for details). Mice were sacriﬁced at
6 h and peritoneal exudate neutrophil counts were determined by light microscopy and ﬂow cytometry. Results are mean  s.e.m. n = 5 mice per group (*P < 0.05
versus MV treated mice by one way ANOVA).
GA 2MG surface expression on plasma microparticles (AnxAV
positive events) from healthy volunteers (HV; n = 15), patients that survive (SS; n = 25) and those that do not
survive the sepsis (SNS; n = 25) as determined by ﬂow-cytometry (see Materials and Methods and supplementary Table S1 for further details; *P < 0.05; ***P < 0.001
versus HV,
#P < 0.05,
###P < 0.01 versus SS by one way ANOVA;
§§§P < 0.01 by two tailed Fisher’s exact test).
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36A2MG to sequester proteinases thereby regulating proteinase
activity during inﬂammatory events (reviewed in Rehman et al,
2013).
In other systems A2MG exerts protective actions inhibiting H2O2
production by polymorphonuclear leukocytes, Trypanozoma cruzi
induced macrophage and cardiomyocyte apoptosis and clearing
unfolded or misfolded proteins from extracellular spaces (reviewed
in Rehman et al, 2013). Hence, our present ﬁndings with A2MG
containing microvesicles and in a clinically relevant model of sepsis
suggest a novel mechanism of action for A2MG, whereby incorpora-
tion of A2MG in microparticles potentiates the endogenous host
responses resulting in enhanced protective actions in sepsis when
compared to sA2MG.
At the site of inﬂammation lipid mediators are biosynthesized
from polyunsaturated fatty acids and regulate both perpetuation
and resolution of inﬂammation (Spite & Serhan, 2010). Mediators
including PG and LT, produced from arachidonic acid, increase
vascular permeability and recruitment of leukocytes to the site(s)
of inﬂammation (Flower & Vane, 1974; Samuelsson, 2012). These
arachidonic acid derived mediators are also responsible for
inﬂammasome-mediated mortality in experimental models of
infection (von Moltke et al, 2012). Docosahexaenoic acid derived
mediators, such as RvD1 and RvD2, possess potent pro-resolving
and tissue protective actions (Spite & Serhan, 2010). These novel
lipid mediators also promote bacterial containment and clearance
in experimental models of sepsis (Spite et al, 2009; Chiang et al,
2012). In the present report we found that both sA2MG and
A2MG-E microparticle administration led to a signiﬁcant reduc-
tion in exudate pro-inﬂammatory eicosanoid levels including
LTB4 and PGD2. Of note, only treatment of CLP mice with
A2MG-E MP led to a signiﬁcant increase in exudate levels of the
pro-resolving RvD1, RvD5 (Chiang et al, 2012) and RvD2 (Spite
et al, 2009), lipid mediators that stimulate resolution and pre-
serve immune vigilance in murine sepsis. In addition, A2M-E MP
administration signiﬁcantly reduced bacterial loads, both at the
site of inﬂammation and systemically, and protected against
hypothermia (Fig 2).
It is noteworthy that sA2MG also displayed mild protective
actions in vivo although these were to a lesser extent than those
displayed by A2M-E MP, especially in terms of survival and regu-
lation of the host responses (Figs 1 and 2). This is in contrast to
results obtained when sA2MG was incubated with isolated leu-
kocytes in vitro where the free protein displayed biological actions
of equal magnitude to those the microparticle bound A2MG (Fig 5
and supplementary Figs S8 and S10). One possible explanation for
these differences between in vivo and in vitro actions for sA2MG
is that this protein, in its receptor binding conformation as
employed in the current experiments, has a very short systemic
half-life, estimated to be of ~4 min in mice (Imber & Pizzo, 1981)
and is primarily cleared by the liver (Shibata et al, 2003). There-
fore these results underscore the notion that incorporation of this
protein into microparticles maximizes the protective actions
exerted by A2MG. This notion was further corroborated by the
ﬁnding that administration of synthetic microvesicles containing
A2MG also displayed protective actions in murine sepsis and
reduced local and systemic inﬂammation, as well as bacterial bur-
dens in a dose-dependent manner, ultimately leading to enhanced
survival (Figs 3 and 4).
Aberrant leukocyte inﬁltration in non-target organs and the
release of noxious intracellular material is responsible for the devel-
opment of multiple organ failure in severe sepsis (Qiu et al, 2000).
A2MG-E MP administration enhanced bacterial containment and
clearance, and produced a discreet alteration in systemic (plasma)
and local (peritoneal exudate) cytokine proﬁles, with a reduction in
pro-inﬂammatory cytokine levels, including IL-6, IL-17 and TNF-a.
In addition, A2MG-E microparticles augmented local and systemic
IFNc and IL-5 levels. Intriguingly both cytokines have been identi-
ﬁed as potential therapeutic interventions for immune compromised
patients with sepsis (Docke et al, 1997; Linch et al, 2012). sA2MG
administration only in part replicated the protective actions of
A2MG-E MP, with upregulation of exudate IFNc levels. This speciﬁc
modulation of local and systemic cytokine levels resulted in a reduc-
tion in systemic inﬂammation and signiﬁcant protection from sec-
ondary organ injury (Fig 2). Collectively, these ﬁndings indicate
that microparticle-A2MG activated endogenous host protective
mechanisms that assure an efﬁcient leukocytic response, mainly
involving neutrophils and possibly macrophages, with effective
clearance of the pathogen and the timely and efﬁcient onset of reso-
lution, with selective engagement of endogenous resolution path-
ways, leading to increased survival.
Poor outcomes in sepsis are in many cases attributable to aber-
rant leukocyte responses that compromise elimination of the
infecting pathogen and predispose to recurrent infective episodes
(Riedemann et al, 2003; Goldenberg et al, 2011). It is now appreci-
ated that a compensatory anti-inﬂammatory response follows, or
more likely accompanies, the systemic inﬂammatory response
syndrome (Reddy & Standiford, 2010), perhaps accounting for the
failure of classical anti-inﬂammatory therapies (vide supra). Leuko-
cytes provide the ﬁrst line of defense against invading pathogens,
including bacteria. Thus, agents that compromise leukocyte func-
tions hamper the host responses, leading to inadequate contain-
ment and uncontrolled systemic inﬂammation (Alves-Filho et al,
2009). A2MG interacts with a member of the lipoprotein receptors,
termed LRP1 (Andersen et al, 2000) that mediates some of the
protective actions displayed by A2MG (Arandjelovic et al, 2007).
In the present study we found that LRP1 was expressed on both
human and mouse neutrophils and mediated the protective actions
exerted by A2MG-E microparticles in murine sepsis (Fig 4). In
addition LRP1 also mediated the pro-phagocytic and bactericidal
actions of A2MG on both neutrophils and macrophages (Fig 5,
supplementary Figs S8 and S10). These ﬁndings are in accord with
the pro-phagocytic actions exerted by A2MG on sheep leukocytes
(Murai et al, 1996) and underscore the protective role of micro-
particle-A2MG in preserving leukocyte responses during sepsis
(Fig 2).
LRP1 was originally identiﬁed as an endocytic receptor; albeit it
is now evident that ligand binding to human LRP1 engages speciﬁc
signaling pathways promoting downstream cellular responses (May
et al, 2005; Shi et al, 2009). In accord with these ﬁndings we
observed that A2MG promoted exposure of a neo-epitope on the
alpha subunit of Mac-1 (CD11b, Fig 7A) and higher neutrophil
adhesion to its counter ligand ICAM-1 (Fig 7B and supplementary
Fig S13). A2MG was also transferred by microparticles onto the
endothelial cell plasma membrane where it promoted neutrophil
adhesion. Together these ﬁndings suggest a model whereby A2MG
deposited onto the endothelial cell plasma membrane can engage
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37LRP1 on the neutrophil leading to the activation of b2-integrins
hence neutrophil ﬁrm adhesion (Fig 7) via signaling pathways that
remain of interest.
At the molecular level, one of the mechanisms responsible for
aberrant neutrophil responses involves binding of endotoxin to TLR
receptors, resulting in upregulation of GRK2 and the consequent
reduction of neutrophil chemotactic receptors, including formyl pep-
tide receptor 1 (Liu et al, 2012) and chemokine receptor CXCR2 (Al-
ves-Filho et al, 2010). CXCR2 down-regulation leads to insufﬁcient
neutrophil recruitment to the site of infection, impaired bacterial
containment, uncontrolled systemic inﬂammation and a poor prog-
nosis (Alves-Filho et al, 2010). A2MG prevented endotoxin medi-
ated GRK2 upregulation, CXCR2 down regulation in neutrophils and
restored neutrophil chemotactic response to IL-8 (Fig 7). These ﬁnd-
ings led us to hypothesize that microparticle-A2MG enhanced sur-
vival by promoting efﬁcient neutrophil recruitment to the site of
infection; a concept that has been postulated for other agents that
are protective in sepsis including IL-33 (Alves-Filho et al, 2010).
This hypothesis was corroborated by the in vivo ﬁndings with
A2MG MV, where administration of these vesicles led to an
enhanced and dose dependent increase in early neutrophil recruit-
ment (i.e. at the 6 h interval) to the peritoneum following CLP
(Fig 7F).
In conclusion, our ﬁndings provide evidence for a novel host
protective mechanism in sepsis mediated by A2MG incorporation
into microparticles. Microparticle-A2MG is functionally transferred
on to endothelial cells plasma membrane where it engages its
receptor on the surface of rolling or tethering leukocytes modulat-
ing their responses to invading pathogens. In complex on-going
systemic response to sepsis, the cellular events instigated by
A2MG ultimately lead to efﬁcient disposal of the invading patho-
gen, upregulation of immunoresolving lipid mediators (e.g. RvD1,
and RvD2) as well as immunomodulatory cytokines (e.g. IL-5 and
IFN-c), resulting in signiﬁcant protection from death in experimen-
tal sepsis.
Moreover we recently found that plasma levels of A2MG con-
taining microparticles are elevated in septic patients compared to
healthy volunteers (Dalli et al, 2013) and here we report that lev-
els of A2MG containing microparticles were signiﬁcantly elevated
in patients that survived sepsis when compared to non-survivors
and healthy volunteers (Fig 7F and supplementary Table S1). In
view of the increasing incidence of sepsis and the failure of
immune suppressive strategies to improve outcome, there is con-
siderable interest in developing novel biomarkers and innovative
treatments for this condition (Riedemann et al, 2003; Russell,
2006; Goldenberg et al, 2011; Wenzel & Edmond, 2012). Also a
mounting body of evidence suggests that an alternative approach
for the treatment of inﬂammatory conditions, including sepsis, is
to employ endogenous agonists to target host pro-resolution
responses (Spite & Serhan, 2010; Levy et al, 2012; Ortega-Gomez
et al, 2013). Our ﬁndings provide the rationale for employing
A2MG containing microparticles as novel early biomarkers for
disease severity and prognosis, for example as noted herein for
sepsis. In addition the present ﬁndings identify A2MG containing
microparticles or microvesicles as a potential therapeutic interven-
tion in patients suffering from severe sepsis/septic shock, espe-
cially when targeted to patients with immune compromise and
recurrent or persistent sepsis.
Materials and Methods
Unless otherwise speciﬁed, materials were obtained from Sigma-
Aldrich Ltd (Poole, UK). Animal work was performed according to
Home Ofﬁce regulations (Guidance on the Operation of Animals,
Scientiﬁc Procedures Act, 1986) and was approved by the Queen
Mary University of London Ethics Committee (London, UK) as well
as Harvard Medical School Standing Committee on Animals guide-
lines for animal care (Protocol 02570). Human cells were prepared
according to a protocol approved by the East London & the City
Local Research Ethics Committee (no. 06/Q605/40; P/00/029 EL-
CHA, London, UK). Plasma samples were obtained from patients
suffering from severe sepsis/septic shock (deﬁned according to The
American College of Chest Physicians/Society of Critical Care Medi-
cine consensus deﬁnitions) caused by community-acquired pneu-
monia (CAP) (deﬁned as a febrile illness associated with cough,
sputum production, breathlessness, leukocytosis and radiological
features of pneumonia acquired in the community or within <2 days
of hospital admission) using a protocol approved by the National
Research Ethics Service (NRES Committee South Central-Berkshire,
original REC Ref numbers: 05/MRE00/38 and 08/H0505/78).
Brieﬂy, 4 ml whole blood was chill centrifuged at 4°C for 10 min at
1600 g. Platelet poor plasma was transferred into cryovials and
stored at 80°C.
Microparticle preparation
Human neutrophils were isolated by density centrifugation from
whole blood as previously described (Dalli et al, 2008). Neutrophils
(2 9 10
7 cells/ml), were either incubated over a HUVEC monolayer
for 20 min at 37°C prior to addition of fMLP (1 lM; 20 min at 37°C),
yielding micro particles that expressed elevated levels of A2MG
(A2MG MP) or incubated with fMLP (1 lM; 20 min at 37°C) in sus-
pension yielding microparticles that expressed low A2MG levels
[more details in Dalli et al (2013)]. Supernatants were collected and
contaminating cells removed by two successive centrifugations
(3000 g; 10 min at 4°C), prior to pelleting the microparticles by ultra-
centrifugation (100 000 g;1ha t4 °C) as described (Dalli et al, 2008).
Microparticlepellets were resuspendedwith Dulbecco phosphatebuf-
fered solution (DPBS) and stored at 80°C prior to further analysis.
Plasma microparticle samples from healthy volunteers or septic
patients were prepared by gradient centrifugation and subsequent
ultracentrifugation, as describe above. Supplementary Table S1
illustrates the demographic characteristics of the donors. For the
septic patients, plasma was obtained within 24 h of admission to
the Intensive Care Unit of participating hospitals.
A2MG microvesicle preparation
A2MG enriched microvesicles (A2MG-MV) were prepared as
described in De Cock et al (2010) for protein loading in polyelectro-
lyte multilayer microvesicles. Brieﬂy, vesicles were fabricated by
alternating deposition of 7 oppositely charged polymer layers of
poly-L-Arginine and dextran sulfate sodium salt with one layer of
ﬂuorescently labeled FITC-poly-L-Lysine (all polymers were pur-
chased from Sigma-Aldrich). These alternated layers constituted the
microvesicle shell that was shown to be well tolerated in vivo
studies (De Cock et al, 2010). These layers are deposited around
co-precipitated CaCO3 porous particles with A2MG added at
a concentration 0.2 mg/ml according to Petrov et al (2005).
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38Multilayer assembly on CaCO3 particles with A2MG was followed
by the dissolution of calcium carbonate using 0.2 M ethylenedi-
aminetetra-acetic acid. Active A2MG (450 lg; BioMac, Leipzig, Ger-
many), remained entrapped into the microvesicles and A2MG levels
were assessed by ELISA (see below for details) as 140 ng/1 9 10
5
microvesicles. As a control, blank microvesicles (no protein incor-
porated; cMV) were used, prepared and handled exactly as the
A2MG-MV but devoid of any protein, and are termed cMV. The
mean diameter of the vesicle was 2–3 lm.
Flow cytometry and Western Blotting
To determine microparticle levels in healthy volunteer and sepsis
patient plasma samples microparticles were double stained using an
anti-CD66b PE-conjugated antibody (1:25; clone G10F5; BioLegend,
Cambridge UK) and Alexa488 conjugated anti-A2MG (5 lg/ml;
Clone 3D1; Thermo Scientiﬁc, Northumberland, UK). In all cases,
microparticles were incubated with the antibodies or relevant iso-
type controls for 45 min at 4°C prior to analysis with a FACSCalibur
ﬂow cytometer (Becton Dickinson, San Jose, CA, USA) using Cell-
QuestTM software (Becton Dickinson).
Surface expression of adhesion molecules on endothelial adhe-
sion were assessed on HUVEC (passage 1–3) stimulated with TNFa
(10 ng/ml; R&D Systems, Abingdon, UK) and incubated with or
without A2MG MP (8 9 10
5/9.6 cm
2/well) for 4 h at 37°C. Expres-
sion of CD62E/P (clone: 1.2B6), CD106 (clone: 1.G11B1), CD31
(clone: WM59) CD54 (clone: HA58), CD99 (clone: DN16) or A2MG
(clone: 257316) were determined by ﬂow cytometry following stan-
dard protocols.
A2MG, in its active conformation (cat no: 05-04; BioMac), was
always employed when added exogenously. Human neutrophils
were incubated with LPS (1 lg/ml) following a 5-min pretreatment
with vehicle (PBS) or active A2MG. For assessment of CD11b neo-
epitope exposure, anti-CD11b FITC-conjugated antibody (clone:
CBRM1/5) was added to the neutrophils in suspension prior to LPS
stimulation (10 min, 37°C). Subsequently, cells were washed and
staining assessed as above. In a separate set of experiments neu-
trophils were pre-incubated with A2MG (0.1–10 nM, 5 min), then
stimulated with LPS (strain 055B:B5 Sigma; 1 lg/ml, 60 min), prior
to washing and assessment of CXCR2 levels using a mouse anti-
human CXCR2 PE-conjugated antibody (clone: 5E8; Biolegend).
In some experiments human neutrophils were incubated with or
without A2MG (10 nM, 5 min, 37°C) prior to LPS stimulation
(1 lg/ml, 60 min, 37°C) and GRK2 expression assessed by Western
blotting (clone:sc-562; 0.5 lg/ml). Proteins were detected using an
ECL detection reagent and visualized on HyperﬁlmTM (GE Health-
care, Buckinghamshire, UK).
Human peripheral blood neutrophils were incubated with PBS or
LPS (1 lg/ml, 1 h, 37°C). Cells were then either taken for staining
or permeabilized using a Cytoﬁx/Cytoperm buffer solution (BD Bio-
sciences, San Jose, CA, USA) prior to staining. Next the neutrophils
incubated with anti-LRP1 antibody (5 lg/ml; clone A2MGr alpha-2;
Invitrogen, Paisley, UK) for 45 min or relevant isotype control and
then with an anti-mouse Alexa Fluor
  488 conjugated antibody
(10 lg/ml; Invitrogen) for 45 min. LRP1 levels are expressed in MFI
units relative to Isotype control.
Bacterial phagocytosis in murine inﬂammatory exudates was
assessed by ﬂow cytometry as in Vaishnava et al (2011) with some
modiﬁcations. Peritoneal exudates were placed in 96 well plates
washed to removed any unphagocytosed bacteria. The cells were
then ﬁxed and permeabilized using Cytoﬁx/Cytoperm buffer solu-
tion (BD Biosciences) for 30 min at 4°C. The cells were the incu-
bated with a solution containing 0.1 mg/ml lysozyme, 100 mM
Tris–HCl and 50 mM EDTA for 5 min on ice. The cells were then
washed with buffer and incubated with 25 lM of bacterial speciﬁc
probe (sequence: GCTGCCTCCCGTAGGAGT) or a non-speciﬁc con-
trol probe (sequence: ACTCCTACGGGAGGCAGC) conjugated to
Alexa Fluor
  488 (Operon, Alameda, CA, USA) and incubated over-
night at 50°C. The cells were then washed 39 in wash buffer and
the extent of phagocytosis was determined by ﬂow cytometry.
Flow chamber
To assess leukocyte-endothelial interactions, HUVEC were plated in
l-Slides VI0.4 (Ibidi, Munchen, Germany). Conﬂuent monolayers
were stimulated with TNF-a (10 ng/ml, 4 h; R&D systems) and incu-
bated with or without A2MG MP (5 9 10
4/0.6 cm
2 channel) for 4 h
at 37°C. In determinate experiments, A2MG MP were pre-incubated
for 15 min with anti-A2MG (5 lg/ml) prior to addition to HUVEC for
4 h, or antibodies were added to HUVEC only 15 min prior to ﬂow
(that is the last 15 min of the 4 h incubation with A2MG MP).
Human neutrophils (1 9 10
6/ml) were perfused over HUVEC at
1 dyne/cm
2 for 8 min, then six random ﬁelds were recorded for 10 s
and images analysed using Image ProPlus 7 (MediaCybernetics,
Bethesda, MD, USA). Neutrophils that remained stationary were
quantiﬁed as adherent.
In a separate set of experiments l-Slides VI0.4 (Ibidi) were coated
using hrICAM-1 (50 lg/ml; R&D Systems) for 60 min at room tem-
perature. Human peripheral blood neutrophils isolated as described
above were pre-incubated for 5 min with vehicle (PBS) or A2MG
(10 nM), subsequently stimulated with LPS (1 lg/ml, 60 min) and
perfused over the ICAM-1 coated chamber at 1 dyne/cm
2 for 8 min.
In a separate set of experiments l-Slides VI0.4 (Ibidi) were
coated using rmICAM-1 fc chimera (12.5 lg/ml; R&D Systems) for
60 min, then blocked with 1% BSA for 30min. Murine blood was
collected in sodium citrate (1:10, 3.2%) and diluted 1:10 in HBSS.
Blood was treated for 15 min with vehicle (PBS) or A2MG (10 nM),
subsequently stimulated with LPS (1 lg/ml, 60 min, 37°C) and ﬂo-
wed over the ICAM-1 coated chamber at 1 dyne/cm
2 for 8 min.
Confocal microscopy
Neutrophils were assessed for surface expression of A2MG receptor
(LRP1) along with the lineage speciﬁc lineage marker (CD11b) under
resting conditions and after LPS incubation (1 lg/ml, 1 h, 37°C).
Cells were labeled with anti-LRP1 unconjugated antibody (5 lg/ml;
clone A2MGr alpha-2; Invitrogen) for 45 min and then with speciﬁc
secondary antibody Alexa Fluor
  488 (10 lg/ml; Invitrogen) for
45 min. Finally, anti-CD11b APC-conjugated antibody (2 lg/ml;
clone ICRF44; eBioscence, Hatﬁeld, UK) was added together with the
relevant isotype controls, for 1 h at 4°C. Cells were then washed with
PBS and re-suspended in deionized H2O and transferred onto on
microscope slides and mounted in Probing Antifade medium (Invi-
trogen) containing DAPI. The staining was visualized using a Zeiss
LSM 510 META scanning confocal microscope (963 oil-immersion
objective) and analysed by Zeiss LSM Imaging software (Carl Zeiss,
Oberkochen, Germany).
HUVEC were plated in l-Slides VI0.4 (Ibidi), and conﬂuent
monolayers were stimulated with TNF-a (10 ng/ml) in presence or
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high MPs (5 9 10
4) for 4 h (37°C). HUVEC were
then ﬁxed with 1% paraformaldehyde (PFA; 10 min, 4°C). Cells
were stained with Alexa Fluor
  633-Agglutinin (1 lg/ml; Invitro-
gen; 20 min, RT) and then blocked for 30 min in PBS containing
5% FBS. Unconjugated primary anti-A2MG antibody (5 lg/ml; R&D
System) was then added for 1 h followed by Alexa Fluor
  594 sec-
ondary antibody (5 lg/ml; Invitrogen) for 45 min. Cells were
washed in PBS, mounted and imaged as above.
Microparticle A2MG-enrichment
Microparticles were obtained from human neutrophils as described
above. Intercalation of active A2MG (0.1 mg per 5 9 10
5 micropar-
ticles) with ﬂuorescent phospholipid (1,2-dioleoyl-sn-glycero-3-
phoshpo-L-serine-N-7-nitro-2-1,3-benzoxadiazol-4-yl; 100 mg; Avanti
Polar Lipids, Alabaster, AL, USA) was performed by aqueous energy
dissemination using a sonic dismembrator (output power 15 W,
15 min, 25°C; Fisher Scientiﬁc, Loughborough, UK) as previously
described (Norling et al, 2011) (supplementary Fig S1). A2MG-E mi-
croparticles were then ultra-centrifuged at 100 000 g to remove any
unbound protein and resuspended in 0.2-lm ﬁltered PBS. Incorpora-
tion of A2MG was conﬁrmed by ﬂow cytometry (BD FACSCanto II;
BD Biosciences) staining with an isoform speciﬁc anti-A2MG anti-
body (Clone a1/IIE7; BioMac).
Coecal ligation and puncture
Coecal ligation and puncture (CLP) was performed in male FVB
mice (5–6 weeks old). The cecum was ligated below the ileo-
caecal valve to produce severe sepsis (Rittirsch et al, 2009). A
through and through puncture was performed with a 20 gauge nee-
dle, followed by one additional puncture in the distal tip of the
cecum. Mice received saline (500 ll s.c.) followed by i.v. adminis-
tration of 100 ll of PBS, sA2MG (0.05 lg) or A2MG-E microparticles
(1 9 10
5) 1 h after closure of the peritoneum. Animal survival was
followed up to day 4. In separate experiments, mice were treated as
above, with control microvesicles (cMV; 10
6/mouse) or A2MG-MV
at the indicated concentrations and sacriﬁced at 6 h or 12 h post
CLP. Body temperature was measured with a thermal probe (FLUKE
Corporation, Everett, WA, USA). Blood was collected by cardiac
puncture, peritoneal lavage ﬂuid and lung tissue were also collected.
Blood and peritoneal bacterial loads were determined by growth on
tryptic soy agar plates. Plasma and peritoneal cytokine levels were
determined by Multiplex array. Peritoneal cells were counted using
Turks solution and differentiated using anti-F4/80 (Clone BM8; Bio-
Legend) and anti-Ly6G (Clone 1A8; BioLegend) antibodies. Neutro-
phil inﬁltration within the lungs was assessed following mechanical
disruption of the tissue and staining for anti-Ly6G.
Using in vivo-JetPEI
TM (Polyplus, Illkirch, France) transfection
reagent as a carrier for delivering plasmids in vivo we administered
30 lg of mock or mouse LRP1 siRNA lentiviral vectors (Applied Bio-
logical Materials Inc., Richmond, VA, USA). The plasmid containing
solution was prepared following manufacturer’s instructions and
the plasmid was delivered by i.v. injection. LRP1 expression in
peripheral blood was determined after 48 h by realtime PCR (see
details below).
Targeted LC-MS/MS-based lipidomics of CLP peritoneal exudates
Exudate lavages were collected and immediately added to two vol-
umes of cold methanol for extraction and work-up as in (Yang et al,
2011). LC-MS-MS identiﬁcation was acquired with an Agilent 1100
series HPLC (Santa Clara, CO, USA) paired with an ABI Sciex Instru-
ments (Framingham, MA, USA) 5500 Q-TRAP linear ion trap quad-
rupole mass spectrometer. The column (Agilent Eclipse Plus C18,
4.6 mm 9 50 mm 9 1.8 lm) was eluted at a ﬂow rate of 0.4 ml/
min with methanol/water/acetic acid (60/40/0.01; v/v/v) ramped
to 80/20/0.01 (v/v/v) after 5 min, 95/5/0.01 (v/v/v) after 8 min,
and 100/0/0.01 after 14 min to wash the column. Instrument con-
trol and data acquisition were performed using Analyst 1.5 software
(ABSciex, Framingham, MA, USA). Ion pair transitions from previ-
ously reported multiple reaction monitoring (MRM) methods were
used for proﬁling and quantitation of RvD1 (375.2/233.1) RvD2
(375.2/175.1), PD1 (359.2/153.1), PGD2 (351.2/189.1), PGE2
(351.2/233.1), PGF2a (353.2/193.1) and LTB4 (335.2/195.1). Criteria
for identiﬁcation were: LC retention time and a minimum of six frag-
ment diagnostic ions on the MS/MS spectrum matching those of
synthetic standards. Deuterated 5S-HETE, PGE2 and LTB4 (Cayman
Chemicals, Ann Arbor, MI, USA, 500 pg) were added prior to extrac-
tion as internal standard for recovery calculations.
Gene expression
Peripheral blood was collected in heparinized syringes from tail
veins of mice that received either mock vector or siRNA carrying
vectors after 48 h. Blood was immediately placed in TRIzol
  (Invi-
trogen, New York, NY, USA) and RNA was extracted following man-
ufacturer’s instructions. RNA quantity and quality was assessed on a
NanoDrop 2000 (ThermoScientiﬁc, Wilmington, DE, USA). cDNA
was obtained using a SuperScript
  III First-Strand Synthesis Super-
Mix and sequence speciﬁc primers for mouse GAPDH and LRP 1 fol-
lowing manufacturer’s instructions. Realtime PCR was performed
using RT
2 mastermix (Qiagen, Manchester, UK) following manufac-
turer’s instructions and loading ~100 ng of cDNA per well.
E. coli phagocytosis and generation of intracellular reactive
oxygen species
Human neutrophils and monocyte derived macrophages were
adhered to plastic and pre-incubated with A2MG in the activated
conformation (1–100 nM), A2MG MP (10
2–10
5) or vehicle for
15 min prior to incubation with pre-labeled E. coli (O6:K2:H1; 50:1
ratio, BacLight) 37°C, 60 min. Non-phagocytosed bacteria were
washed off and extracellular ﬂuorescence quenched using Trypan
blue (1:50 dilution). The number of phagocytosed cells was assessed
using a Spectra Max M3 (Molecular Devices, Sunnyvale, CA, USA)
plate reader by measuring ﬂuorescence emission at 525 nM.
In separate experiments human neutrophils and monocyte
derived macrophages were incubated with CM-H2DCFDA (5 lM) for
30 min prior to washing and plating on a 96 well plate. Nonadher-
ent cells were removed and cells incubated A2MG in the activated
conformation (1–100 nM), A2MG MP (10
2–10
5) or vehicle for
15 min prior to incubation with E. coli (O6:K2:H1; 50:1 ratio) for an
additional 30 min at 37°C. Probe oxidation was determined using a
ﬂuorescent plate reader.
Neutrophil chemotaxis
Human neutrophils were isolated as detailed above and resus-
pended at 4 9 10
6/ml in PBS containing 0.05% BSA. These were
then incubated with either PBS or A2MG for 15 min prior to incuba-
tion with LPS (1 lg/ml) for 15 min. Chemotaxis towards IL8
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40(100 ng/ml) was then assessed using Neuroprobe 96 well
ChemoTx
  chambers with 3 lM pore size over 90 min.
A2MG ELISA
Standards (0.005–5 lg/ml), A2M-E MP or A2MG microparticles
were transferred in 100 ll to a 96 well high binding plate (Corning
 
Costar
 ; Sigma-Aldrich) and incubated overnight at 4°C. Plates were
washed three times and blocked using PBS containing 2% BSA
(RT). After 1 h plates were washed and incubated with anti-A2MG
(1:50 000; BioMac) for 2 h (RT). Plates were then washed and incu-
bated with anti-mouse HRP conjugated antibody (1:5000; Invitro-
gen) for 2 h at RT. Subsequently plates were washed and incubated
with TMB substrate buffer (R&D System) for 30 min at RT. The
reaction was stopped with 1 N sulphuric acid and absorbance at
450 nm was measured on a plate reader.
Statistical analyses
Experiments were performed in triplicate and results expressed
as Mean  s.e.m. Statistical differences were determined using
one-way analysis of variance or two-tailed unpaired Student’s t-
test as appropriate. Kaplan–Meier survival curves were analyzed
using a one-tailed log-rank test using GraphPad Prism
TM (GraphPad
Software, La Jolla, CA, USA). A P value < 0.05 was taken as sig-
niﬁcant for rejection of the null hypothesis.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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